| Autor: |
Huma, Shehwana, Ayse G, Keskus, Sila E, Ozdemir, Azer A, Acikgöz, Rumeysa, Biyik-Sit, Ilgin, Cagnan, Damla, Gunes, Ermira, Jahja, Sahika, Cingir-Koker, Gizem, Olmezer, Ceren, Sucularli, Ozlen, Konu |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Cellular oncology (Dordrecht). 44(2) |
| ISSN: |
2211-3436 |
| Popis: |
Cholinergic signals can be important modulators of cellular signaling in cancer. We recently have shown that knockdown of nicotinic acetylcholine receptor subunit alpha 5, CHRNA5, diminishes the proliferative potential of breast cancer cells. However, modulation of CHRNA5 expression in the context of estrogen signaling and its prognostic implications in breast cancer remained unexplored.Meta-analyses of large breast cancer microarray cohorts were used to evaluate the association of CHRNA5 expression with estrogen (E2) treatment, estrogen receptor (ER) status and patient prognosis. The results were validated through RT-qPCR analyses of multiple E2 treated cell lines, CHRNA5 depleted MCF7 cells and across a breast cancer patient cDNA panel. We also calculated a predicted secondary (PS) score representing direct/indirect induction of gene expression by E2 based on a public dataset (GSE8597). Co-expression analysis was performed using a weighted gene co-expression network analysis (WGCNA) pipeline. Multiple other publicly available datasets such as CCLE, COSMIC and TCGA were also analyzed.Herein we found that CHRNA5 expression was induced by E2 in a dose- and time-dependent manner in breast cancer cell lines. EROur findings strongly associate increased expression of CHRNA5 and its co-expression network with secondary E2 signaling and a worse prognosis in breast cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink